摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-propyl-catechin

中文名称
——
中文别名
——
英文名称
8-propyl-catechin
英文别名
(2R,3S)-2-(3,4-dihydroxyphenyl)-8-propyl-3,4-dihydro-2H-chromene-3,5,7-triol
8-propyl-catechin化学式
CAS
——
化学式
C18H20O6
mdl
——
分子量
332.353
InChiKey
VWEYDCHOMYRFPX-DLBZAZTESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    110
  • 氢给体数:
    5
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    儿茶提取物palladium dihydroxide 咪唑N-溴代丁二酰亚胺(NBS)正丁基锂氢氟酸氢气 、 sodium hydride 作用下, 以 四氢呋喃甲醇二氯甲烷N,N-二甲基甲酰胺乙腈 为溶剂, 反应 1.0h, 生成 8-propyl-catechin
    参考文献:
    名称:
    Synthesis and Preliminary Anticancer Activity Studies of C4 and C8-Modified Derivatives of Catechin Gallate (CG) and Epicatechin Gallate (ECG)
    摘要:
    We have developed an improved and reliable method for stereoselective functionalization at C4 of naturally occurring (+)-catechin. Our method utilizes DDQ oxidation followed by trapping of the quinonemethide intermediate with allyl alcohol. The quinonemethide intermediate can be regenerated from the allyl ether by exposure to boron trifluoride diethyl etherate. This reactive intermediate can be trapped with a wide range of external nucleophiles. NBS bromination, lithium halogen exchange, and alkylation gave access to C8-allyl derivatives of (+)-catechin, and this allyl group was used in a series of cross-metathesis experiments to prepare novel dimeric catechin-derived products. Gallate ester derivatives of the novel C4- and C8-substituted catechins were prepared, and these materials were screened for potential anticancer activity in a range of human cancer cell lines. From these preliminary cytotoxicity assays (MTT) we found that C8-propyl-catechin gallate was more active (IC50 = 31 mu M) than catechin gallate (CG, IC50 = 53 mu M) or epicatechin gallate (ECG, IC50 = 76 mu M) against the colorectal adenocarcinoma cell line HCT116. Differential sensitivity in pancreas (Pan1), bladder (RT112), stomach (MGLVA1), liver (HepG2), and fibroblasts (46Br.1G1) cell lines was also observed.
    DOI:
    10.1021/jo061740e
点击查看最新优质反应信息

文献信息

  • BALLENEGGER, M. E.;RIMBAULT, C. G.;ALBERT, A. I.;WEITH, A. J.;COURBAT, P.+
    作者:BALLENEGGER, M. E.、RIMBAULT, C. G.、ALBERT, A. I.、WEITH, A. J.、COURBAT, P.+
    DOI:——
    日期:——
  • Synthesis and Preliminary Anticancer Activity Studies of C4 and C8-Modified Derivatives of Catechin Gallate (CG) and Epicatechin Gallate (ECG)
    作者:Christopher J. Hayes、Benjamin P. Whittaker、Susan A. Watson、Anna M. Grabowska
    DOI:10.1021/jo061740e
    日期:2006.12.1
    We have developed an improved and reliable method for stereoselective functionalization at C4 of naturally occurring (+)-catechin. Our method utilizes DDQ oxidation followed by trapping of the quinonemethide intermediate with allyl alcohol. The quinonemethide intermediate can be regenerated from the allyl ether by exposure to boron trifluoride diethyl etherate. This reactive intermediate can be trapped with a wide range of external nucleophiles. NBS bromination, lithium halogen exchange, and alkylation gave access to C8-allyl derivatives of (+)-catechin, and this allyl group was used in a series of cross-metathesis experiments to prepare novel dimeric catechin-derived products. Gallate ester derivatives of the novel C4- and C8-substituted catechins were prepared, and these materials were screened for potential anticancer activity in a range of human cancer cell lines. From these preliminary cytotoxicity assays (MTT) we found that C8-propyl-catechin gallate was more active (IC50 = 31 mu M) than catechin gallate (CG, IC50 = 53 mu M) or epicatechin gallate (ECG, IC50 = 76 mu M) against the colorectal adenocarcinoma cell line HCT116. Differential sensitivity in pancreas (Pan1), bladder (RT112), stomach (MGLVA1), liver (HepG2), and fibroblasts (46Br.1G1) cell lines was also observed.
查看更多